MedTrace Logo

Effects of Alternate Nostril Breathing and Bellows Breath in COPD Patients

NCT07719192 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-07-22

No results posted yet for this study

Summary

COPD is a common respiratory disease characterized by progressive airflow obstruction, dyspnea, chronic cough, and sputum production. Alternate nostril breathing and bellows breath are pranayama-based breathing techniques that may improve respiratory function and overall well-being. This randomized clinical trial aims to compare the effects of these techniques on sputum clearance, pulmonary function tests, and quality of life in COPD patients. The study will be conducted at Punjab Institute of Cardiology using convenient sampling. Participants will be divided into two groups: Group A will perform alternate nostril breathing, while Group B will perform bellows breath exercises for 15-20 minutes daily over 3-4 weeks. Outcome measures include sputum clearance, spirometry, and quality of life questionnaires. Data will be analyzed using SPSS with significance set at p \< 0.05. The study may support the use of cost-effective, noninvasive breathing techniques for improving pulmonary function and quality of life in COPD patients.

Conditions

  • COPD (Chronic Obstructive Pulmonary Disease)

Interventions

OTHER

alternate nostril breathing

This technique includingstress reduction,improved respiratory health and enhanced mental clarity. Participants will then be instructed to perform this activity 15 to 20 min/day for 4 days/week for 3to 4 weeks.

OTHER

bellows breath

This technique drain the excess phlegm from brain. It improves awareness, focus concentration and productivity. Participants will then be instructed to performthis activity 10 to 15 min/day for 5 days/week for 3 to 4 weeks.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Arjumand Bano, MS · Riphah International University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2026-08-01
Completion
2026-08-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07719192 on ClinicalTrials.gov